News

Astro's Interpretation of the Phase II CONDOR trial suggests that the immune checkpoint inhibitor durvalumab is tolerable among heavily pre-treated patients with recurrent or metastatic…
Read More...

Astro indicates positive results of  phase II OPTIMA Clinical Trial signifying that patients with head and neck cancers associated with the human papillomavirus (HPV), including those…
Read More...

Cytobank and the U.S Food and Drug Administration collaborate to develop machine learning-based methods for characterizing the morphology of multipotent mesenchymal stromal cells…
Read More...

Quidel Corporation who is known for providing diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, sought 510 (k) Clearance from the United…
Read More...

Degenerative disc disease has long been considered an inseparable part of aging but new breakthrough research from SpinalCyte suggests a new cell-based therapy could provide a cure for…
Read More...

Biopharmaceutical company MOLOGEN AG declared having signed a license deal for the Chinese territory and a global co-development agreement between MOLOGEN and ONCOLOGIE Inc. for its…
Read More...

In a bid to treat metastatic radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC), Exelixis declared results from a Phase 2 Investigator-sponsored trial of cabozantinib.…
Read More...

Merck declared that it will rescind protocol 019 also termed as the APECS study assessing verubecestat (MK-8931), an investigational small molecule inhibitor of the beta-site amyloid…
Read More...

European Commission extends approval to Celltrion's Herzuma for treatment of patients with early breast Cancer, metastatic breast cancer or metastatic gastric cancer whose tumors have…
Read More...

Horizon Discovery Group plc announces that it has entered into a non-exclusive out-licensing agreement with a US-based immuno-oncology therapeutics developer for Horizon's proprietary…
Read More...

DNAnexus announced the availability of its Clinical Trial Solution (CTS) which streamlines the use of next-generation sequencing (NGS) data in regulated clinical trials. The company…
Read More...

Applied Therapeutics announced initiation of a Phase 1 clinical trial for AT-001, an oral small molecule in development for diabetic complications. The Phase 1 clinical trial is a…
Read More...

Teva Pharmaceutical announced the launch of generic version of Syprine (trientine hydrochloride) capsules, 250 mg, in the U.S. Trientine hydrochloride is used in the treatment of…
Read More...

LakePharma announced the launch of the LakePharma MicroBiomanufacturing (GMP) Center in Hopkinton, MA. Located at 35 South Street, the newly-acquired 69,000-square foot building…
Read More...

ProBioGen announced the signature of a non-exclusive license agreement on its proprietary human Artificial Lymph Node (HuALN) platform technology with TEVA. The unique human Artificial…
Read More...

Results from the Phase 1/2 trial (NEO1) and its ongoing extension study (NEO-EXT) show consistent safety data for Sanofi’s investigational avalglucosidase alfa (neoGAA) in patients with…
Read More...

ERT announced advanced respiratory clinical trial services that centrally collect lung function data using the Forced Oscillation Technique (FOT). This solution is available immediately…
Read More...

Bavarian Nordic A/S announced positive results from a Phase 3 pivotal study of its investigational, non-replicating smallpox vaccine, IMVAMUNE. The study achieved both of its primary…
Read More...

Circassia Pharmaceuticals announces that it has received a multi-year Innovative Technology contract for its NIOX VERO asthma management products from Vizient, Inc., the largest…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx® (secukinumab), the first interleukin-17A (IL-17A) inhibitor approved to treat…
Read More...